Please join our experienced panel for a review of key takeaways from FDA’s 2018 drug and device advertising and promotion enforcement letters and a discussion of related regulatory developments. Learn the issues that were most commonly raised in last year’s letters, as well as other important legal and regulatory developments, and what these could mean for your business, including:
- OPDP, APLB, and CDRH enforcement overview
- 2018 advertising and promotion guidance documents
- Evolving approaches to risk disclosure
- OPDP research and guidance agendas
- Predictions for what is expected in 2019
Thursday, February 21, 2019
12:30 P.M. – 1:30 P.M. ET
CLE
CLE credit will be applied for in CA, GA, IL, NY, TX and, if needed, NC and VA. Attendees will receive a Uniform Certificate of Attendance via email approximately 30 days after the program to seek CLE credit in other jurisdictions. New York lawyers: This program is considered transitional and non-transitional in content. The interactive webinar format is synchronous and approved for all lawyers. King & Spalding LLP / 1180 Peachtree Street, Atlanta, GA 30309 | CA Provider # 10947.
If you have questions concerning this Roundtable Webinar, e-mail lifesciences-healthcare@kslaw.com.